Australia's TGA Delists Andrographis; Botanical Adulteration Persists; Perimenopause Category Expands
The Australian TGA's decision to delist Andrographis paniculata impacts product formulation and market access, while persistent botanical adulteration demands enhanced supply chain vigilance. Simultaneously, the emergence of perimenopause as a distinct supplement category offers new product development opportunities.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Regulatory pressure on specific botanical ingredients continues to reshape product portfolios, with the Australian Therapeutic Goods Administration (TGA) confirming the removal of Andrographis paniculata from permitted supplement ingredients. This decision, effective by September 2026, stems from documented reports of severe, unpredictable allergic reactions. Manufacturers and brand owners currently utilising Andrographis in formulations distributed in Australia face an immediate need for product reformulation or market withdrawal. The two-year transition period is critical for managing inventory, reformulating, and re-registering products to avoid compliance breaches and potential product recalls.
Concurrently, the issue of botanical ingredient adulteration remains a significant challenge, particularly for high-value and high-demand herbs. Industry reports indicate that ingredients such as Ginkgo biloba continue to exhibit high rates of adulteration, driven by supply chain pressures and economic incentives. This necessitates heightened due diligence for procurement teams, including advanced analytical testing protocols (e.g., HPTLC, DNA barcoding) and stricter supplier qualification. The financial implications include increased testing costs and potential damage to brand reputation from non-compliant or ineffective products.
Conversely, the supplement market is witnessing the targeted growth of niche categories, exemplified by the emerging focus on perimenopause. Brands are capitalising on the demand for specific, hormone-free formulations designed to address the broader physiological changes experienced by women aged approximately 40 to 55. This trend underscores a shift towards more precise consumer targeting, moving beyond general menopausal support to cater to distinct life stages with tailored ingredient profiles and benefit claims. Contract manufacturers should monitor this space for increasing demand for complex, multi-ingredient blends and consumer-friendly delivery formats.
What this means for Australia
Australian brand owners must immediately audit their portfolios for Andrographis inclusion, initiating reformulation strategies to meet the September 2026 TGA deadline; failure to comply will result in mandatory market exit for affected products. Procurement leads must enhance supplier validation and third-party testing for all botanical ingredients, particularly Ginkgo, to mitigate adulteration risks and safeguard product integrity under TGA manufacturing codes. The growing perimenopause category represents a significant market opportunity; brands can gain first-mover advantage by developing clinically-backed, hormone-free formulations targeting this underserviced demographic, securing shelf space in competitive retail channels like Chemist Warehouse and TerryWhite Chemmart.
Many leading brands in this category are manufactured in partnership with Supplement Factory.